Afatinib + Cisplatin + Gemcitabine

The combination of afatinib + cisplatin + gemcitabine is a treatment regimen that has been studied in clinical trials, particularly for advanced cancers including non-small-cell lung cancer (NSCLC) and cholangiocarcinoma (CCA). ## Efficacy and Clinical Outcomes In Asian patients with EGFR mutation-positive non-small-cell lung cancer, afatinib as a single agent showed significantly longer median progression-free survival (11.0 months) compared to the gemcitabine and cisplatin combination (5.6 months)[1][4]. This was demonstrated in the LUX-Lung 6 study, which was a randomized, open-label phase III trial comparing these treatments as first-line options[5]. However, when afatinib was tested as an add-on to standard gemcitabine/cisplatin chemotherapy in patients with advanced cholangiocarcinoma, it failed to show survival benefits[2]. In this phase I study, the median overall survival was 7.7 months and median progression-free survival was 6.0 months[2]. ## Safety Profile The safety profile of this combination shows distinct patterns of adverse events: - When afatinib was administered with gemcitabine/cisplatin in cholangiocarcinoma patients, diarrhea and hematological disorders were the most common adverse events[2]. - In comparative studies between afatinib monotherapy and gemcitabine/cisplatin, afatinib-treated patients experienced more diarrhea and rash, while gemcitabine/cisplatin-treated patients had more nausea, vomiting, and leucopenia[4]. ## Dosing Information In the cholangiocarcinoma study, 30 mg of afatinib could be safely administered as an add-on to 80% of standard dose gemcitabine/cisplatin[2]. The treatment was given continuously with afatinib administered orally while gemcitabine and cisplatin were given intravenously[2]. ## Biomarker Analysis Extensive biomarker analysis was conducted in some studies: - Almost all cholangiocarcinoma patients overexpressed EGFR on their tumor tissues, but none expressed mutations in Exons 18, 19, and 21[2]. - Non-responders showed higher variation of VEGF-C, VEGF-D, leptin, and sEGFR in their sera[2]. - In NSCLC studies, patients were screened for EGFR mutations (mostly Exon 19 deletion or Leu858Arg) to determine eligibility for afatinib treatment[4]. This combination represents an attempt to enhance standard chemotherapy with targeted therapy, though results have varied by cancer type and patient population.